Molecular immunology · 2026
iPSC-derived polyvalent vaccines as ontogenetically informed immunogens toward overcoming immune refractoriness in microsatellite-stable colorectal cancer: An emerging frontier in cancer immunotherapy.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kumar Abhishek, Dwivedi Dyumn, Ghosh Neha, Gopalakrishnan Kesavaperumal, Rahamathulla Mohamed, Ahmed Mohammed Muqtader, Nair Chandralekha, Singh Dewang, Singh Randhir, Das Uddalak
Аннотация
BACKGROUND: Colorectal carcinoma (CRC) exerts a growing global disease burden, with microsatellite-stable/proficient mismatch repair (MSS/pMMR) tumors exhibiting intrinsic refractoriness to immune-checkpoint blockade (ICB) owing to low tumor mutational burden, limited neoantigenicity, and an immunosuppressive tumor microenvironment (TME) dominated by regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs).
SCOPE: This review synthesizes evidence on induced pluripotent stem cell (iPSC)-derived polyvalent vaccines as ontogenetically recapitulative immunogens, evaluating their mechanistic basis, preclinical efficacy across cancer models, and translational prospects in MSS CRC.
KEY FINDINGS: Reprogramming induces re-expression of oncofetal tumor-associated antigens, including cancer-testis antigens (NY-ESO-1, MAGE-A3) and aberrant glycoforms of CEA and MUC1, that are natively shared between iPSCs and CRC cells. Clinically actionable neoepitopes such as KRAS^G12D/V are not a consequence of reprogramming itself but can be introduced into iPSCs by deliberate genetic engineering (neoantigen-augmented iPSCs), complementing this native oncofetal repertoire and broadening the antigenic payload available for epitope spreading following vaccine-induced tumor cell death. Irradiated autologous or syngeneic iPSCs, delivered with TLR9 agonists, drive CD8⁺ cytotoxic T-cell activation, Th1 polarization, perforin/granzyme-mediated cytolysis, and favorable effector-to-suppressor ratios. Preclinical models of melanoma, pancreatic ductal adenocarcinoma, and MSS CRC demonstrate prophylactic and therapeutic efficacy, with neoantigen-enhanced iPSCs synergizing with radiotherapy-induced DAMPs to achieve durable regressions and memory T-cell formation.
CONCLUSIONS: Translational priorities include CRISPR-engineered hypoimmunogenic iPSC platforms, GMP-compatible non-integrating reprogramming, and combinatorial integration with STING agonists, ICB, CAR-NK cells, and LNP-mRNA constructs to enable biomarker-guided clinical deployment in minimal-residual-disease CRC.
SCOPE: This review synthesizes evidence on induced pluripotent stem cell (iPSC)-derived polyvalent vaccines as ontogenetically recapitulative immunogens, evaluating their mechanistic basis, preclinical efficacy across cancer models, and translational prospects in MSS CRC.
KEY FINDINGS: Reprogramming induces re-expression of oncofetal tumor-associated antigens, including cancer-testis antigens (NY-ESO-1, MAGE-A3) and aberrant glycoforms of CEA and MUC1, that are natively shared between iPSCs and CRC cells. Clinically actionable neoepitopes such as KRAS^G12D/V are not a consequence of reprogramming itself but can be introduced into iPSCs by deliberate genetic engineering (neoantigen-augmented iPSCs), complementing this native oncofetal repertoire and broadening the antigenic payload available for epitope spreading following vaccine-induced tumor cell death. Irradiated autologous or syngeneic iPSCs, delivered with TLR9 agonists, drive CD8⁺ cytotoxic T-cell activation, Th1 polarization, perforin/granzyme-mediated cytolysis, and favorable effector-to-suppressor ratios. Preclinical models of melanoma, pancreatic ductal adenocarcinoma, and MSS CRC demonstrate prophylactic and therapeutic efficacy, with neoantigen-enhanced iPSCs synergizing with radiotherapy-induced DAMPs to achieve durable regressions and memory T-cell formation.
CONCLUSIONS: Translational priorities include CRISPR-engineered hypoimmunogenic iPSC platforms, GMP-compatible non-integrating reprogramming, and combinatorial integration with STING agonists, ICB, CAR-NK cells, and LNP-mRNA constructs to enable biomarker-guided clinical deployment in minimal-residual-disease CRC.